Bshara Sleem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bshara Sleem has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Mariam Arabi
American University of Beirut Medical Center
5 shared publications Christophe El Rassi
Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon
2 shared publications- Christophe El Rassi
Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon
2 shared publications - Fadi Bitar
American University of Beirut Medical Center
2 shared publications - Jad Abdul Khalek
Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon
2 shared publications - Maria Abou Mansour
Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon
2 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- p. 1-9
Pericarditis in COVID-19: a focus on the paediatric population
Background: COVID-19, caused by SARS-CoV-2, is primarily a respiratory illness but may cause cardiovascular complications, including pericarditis. Pediatric SARS-CoV-2-associated pericarditis remains uncommon and likely underreported. This review summarizes the epidemiology, pathophysiology, clinical presentation, diagnosis, management, and outcomes of pericarditis associated with SARS-CoV-2 infection in children. Methods: We narratively reviewed the available literature on SARS-CoV-2-associated pericarditis in the pediatric population, including isolated acute pericarditis, myopericarditis, pericardial effusion, cardiac tamponade, and pericardial involvement in multisystem inflammatory syndrome in children (MIS-C). Results: The true incidence of pediatric SARS-CoV-2-associated pericarditis remains unclear. Reported cases suggest that older children and adolescents are more commonly affected, typically presenting with chest pain, fever, dyspnea, or tachycardia, whereas younger children may exhibit nonspecific symptoms. Diagnosis relies on clinical criteria supported by electrocardiography, echocardiography, inflammatory markers, and cardiac biomarkers, with cardiac magnetic resonance imaging useful when myocardial involvement is suspected. Available evidence suggests a predominantly immune-mediated pathophysiology involving cytokine dysregulation and systemic inflammation, with limited evidence of direct viral invasion. Management is largely extrapolated from established pediatric pericarditis principles and adult data. Nonsteroidal anti-inflammatory drugs and colchicine are first-line therapies, while corticosteroids or intravenous immunoglobulin may be considered in selected inflammatory or MIS-C-associated cases, and interleukin-1 blockade in refractory or recurrent disease. Most affected children recover, although severe pericardial effusion, tamponade, and recurrence have been reported. Conclusion: Pediatric SARS-CoV-2-associated pericarditis encompasses a spectrum of clinical presentations and generally carries a favorable prognosis. Nevertheless, potentially serious complications emphasize the importance of early recognition, differentiation from myocarditis and MIS-C, and structured follow-up.
- 13 November 2026
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- p. 1-9
Open AccessPericarditis in COVID-19: a focus on the paediatric population
Background: COVID-19, caused by SARS-CoV-2, is primarily a respiratory illness but may cause cardiovascular complications, including pericarditis. Pediatric SARS-CoV-2-associated pericarditis remains uncommon and likely underreported. This review summarizes the epidemiology, pathophysiology, clinical presentation, diagnosis, management, and outcomes of pericarditis associated with SARS-CoV-2 infection in children. Methods: We narratively reviewed the available literature on SARS-CoV-2-associated pericarditis in the pediatric population, including isolated acute pericarditis, myopericarditis, pericardial effusion, cardiac tamponade, and pericardial involvement in multisystem inflammatory syndrome in children (MIS-C). Results: The true incidence of pediatric SARS-CoV-2-associated pericarditis remains unclear. Reported cases suggest that older children and adolescents are more commonly affected, typically presenting with chest pain, fever, dyspnea, or tachycardia, whereas younger children may exhibit nonspecific symptoms. Diagnosis relies on clinical criteria supported by electrocardiography, echocardiography, inflammatory markers, and cardiac biomarkers, with cardiac magnetic resonance imaging useful when myocardial involvement is suspected. Available evidence suggests a predominantly immune-mediated pathophysiology involving cytokine dysregulation and systemic inflammation, with limited evidence of direct viral invasion. Management is largely extrapolated from established pediatric pericarditis principles and adult data. Nonsteroidal anti-inflammatory drugs and colchicine are first-line therapies, while corticosteroids or intravenous immunoglobulin may be considered in selected inflammatory or MIS-C-associated cases, and interleukin-1 blockade in refractory or recurrent disease. Most affected children recover, although severe pericardial effusion, tamponade, and recurrence have been reported. Conclusion: Pediatric SARS-CoV-2-associated pericarditis encompasses a spectrum of clinical presentations and generally carries a favorable prognosis. Nevertheless, potentially serious complications emphasize the importance of early recognition, differentiation from myocarditis and MIS-C, and structured follow-up.
- Open Access
- 3 October 2026
- Published by Elsevier in Biomedical Journal
Harnessing Acoustic Energy Against Orthopedic Biofilms: Ultrasound-Based Therapeutic Strategies for Implant-Associated and Bone Infections
- 3 October 2026
- Published by Elsevier in Biomedical Journal
Open AccessHarnessing Acoustic Energy Against Orthopedic Biofilms: Ultrasound-Based Therapeutic Strategies for Implant-Associated and Bone Infections
- Open Access
- 19 January 2026
- Published by SAGE Publications in Sage Open Pediatrics
- Vol. 13
Kawasaki Disease Versus Multisystem Inflammatory Syndrome in Children: Exploring the Complexities of Pediatric Cardiac Inflammatory Disorders
Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C) are both pediatric inflammatory conditions that pose significant challenges in diagnosis and management due to their overlapping clinical features and distinct pathophysiological profiles. KD is a well-established acute vasculitis that primarily affects children under 5. In contrast, MIS-C is a recently identified condition associated with SARS-CoV-2 infection, typically affecting older children and adolescents. Reported mortality for MIS-C remains below 2%, compared with less than 0.1% for KD, although both can result in significant cardiac morbidity if untreated. This review highlights the critical differences between KD and MIS-C, including their genetic underpinnings, clinical manifestations, and responses to treatment. While KD has a well-established treatment protocol involving intravenous immunoglobulin and aspirin, MIS-C treatment is still evolving. The manuscript underscores the importance of distinguishing between these conditions for accurate diagnosis and tailored treatment, which is crucial for improving patient outcomes.
- 19 January 2026
- Published by SAGE Publications in Sage Open Pediatrics
- Vol. 13
Open AccessKawasaki Disease Versus Multisystem Inflammatory Syndrome in Children: Exploring the Complexities of Pediatric Cardiac Inflammatory Disorders
Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C) are both pediatric inflammatory conditions that pose significant challenges in diagnosis and management due to their overlapping clinical features and distinct pathophysiological profiles. KD is a well-established acute vasculitis that primarily affects children under 5. In contrast, MIS-C is a recently identified condition associated with SARS-CoV-2 infection, typically affecting older children and adolescents. Reported mortality for MIS-C remains below 2%, compared with less than 0.1% for KD, although both can result in significant cardiac morbidity if untreated. This review highlights the critical differences between KD and MIS-C, including their genetic underpinnings, clinical manifestations, and responses to treatment. While KD has a well-established treatment protocol involving intravenous immunoglobulin and aspirin, MIS-C treatment is still evolving. The manuscript underscores the importance of distinguishing between these conditions for accurate diagnosis and tailored treatment, which is crucial for improving patient outcomes.
- Open Access
- 31 March 2025
- Published by Open Medical Publishing in Orthopedic Reviews
- Vol. 17
From Bone To Blood Flow: Tissue Engineering In Orthopedics – A Narrative Review
Musculoskeletal injuries and degenerative conditions necessitate advanced regenerative solutions. Tissue engineering has emerged as a pivotal field in orthopedic care, particularly in vascularized bone and cartilage regeneration. This narrative review examines the latest advancements in vascular tissue engineering, including scaffold design, cell-based techniques, and growth factor delivery. A comprehensive literature search was conducted using PubMed, ScienceDirect, and Google Scholar, focusing on innovations and challenges in the field. Vascularized bone grafts (VBGs) outperform non-vascularized counterparts in promoting healing and integration. Advances in scaffold materials, such as smart scaffolds and hybrid biomaterials, enhance osteogenesis and angiogenesis. Cellular therapies, utilizing mesenchymal stem cells and induced pluripotent stem cells, synergistically improve vascularization and bone regeneration. Growth factors like VEGF and bone morphogenic protein (BMP-2), integrated with innovative delivery systems, enable sustained angiogenic stimulation and scaffold integration. While significant strides have been made, challenges persist in achieving full vascular integration and replicating native tissue architecture. Innovations in scaffold technology and vascular surgery techniques hold promise for transforming orthopedic tissue engineering and improving patient outcomes.
- 31 March 2025
- Published by Open Medical Publishing in Orthopedic Reviews
- Vol. 17
Open AccessFrom Bone To Blood Flow: Tissue Engineering In Orthopedics – A Narrative Review
Musculoskeletal injuries and degenerative conditions necessitate advanced regenerative solutions. Tissue engineering has emerged as a pivotal field in orthopedic care, particularly in vascularized bone and cartilage regeneration. This narrative review examines the latest advancements in vascular tissue engineering, including scaffold design, cell-based techniques, and growth factor delivery. A comprehensive literature search was conducted using PubMed, ScienceDirect, and Google Scholar, focusing on innovations and challenges in the field. Vascularized bone grafts (VBGs) outperform non-vascularized counterparts in promoting healing and integration. Advances in scaffold materials, such as smart scaffolds and hybrid biomaterials, enhance osteogenesis and angiogenesis. Cellular therapies, utilizing mesenchymal stem cells and induced pluripotent stem cells, synergistically improve vascularization and bone regeneration. Growth factors like VEGF and bone morphogenic protein (BMP-2), integrated with innovative delivery systems, enable sustained angiogenic stimulation and scaffold integration. While significant strides have been made, challenges persist in achieving full vascular integration and replicating native tissue architecture. Innovations in scaffold technology and vascular surgery techniques hold promise for transforming orthopedic tissue engineering and improving patient outcomes.
- Open Access
- 13 March 2025
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 35 (4) , 798-804
Chylothorax: a rare postoperative complication in paediatric cardiac surgery patients – a 15-year retrospective study from a tertiary care centre in a developing country
Chylothorax, a postoperative complication of CHD surgery, involves chyle accumulation in the pleural cavity, posing challenges in diagnosis and management. This retrospective study investigates the prevalence, aetiology, management, and outcomes of postoperative chylothorax in paediatric patients undergoing cardiac corrective surgery at a tertiary care centre over 15 years. Medical records of paediatric patients who underwent cardiothoracic surgery at the Children’s Heart Center at the American University of Beirut Medical Center between 2007 and 2022 were retrospectively reviewed. Data collection included demographic characteristics, blood parameters, chylous fluid characteristics, diagnostic criteria, treatment modalities, and hospitalisation details. Ethical approval was obtained, and descriptive statistics were employed using SAS 9.4. Among 2,997 children who underwent cardiothoracic surgery, nineteen cases of postoperative chylothorax were identified. The majority were females (63.2%) with a median age of 9 months. Glenn, Fontan, and Blalock–Taussig shunt-related surgeries were the most common operations associated with chylothorax. Single ventricle physiology was the predominant CHD observed (58%). Diagnosis relied primarily on clinical presentation, imaging studies, and triglyceride levels in pleural fluid. Treatment options included conservative dietary modifications, medical therapy such as octreotide, and surgical intervention if necessary. No mortalities were reported, and patients were adequately followed up. This study sheds light on postoperative chylothorax in paediatric cardiac patients, offering insights into its epidemiology, aetiology, clinical features, and treatment outcomes. While conservative and medical approaches effectively managed chylothorax in this group, larger studies are needed to develop standardised diagnostic and treatment protocols, improving outcomes in paediatric patients with postoperative chylothorax.
- 13 March 2025
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 35 (4) , 798-804
Open AccessChylothorax: a rare postoperative complication in paediatric cardiac surgery patients – a 15-year retrospective study from a tertiary care centre in a developing country
Chylothorax, a postoperative complication of CHD surgery, involves chyle accumulation in the pleural cavity, posing challenges in diagnosis and management. This retrospective study investigates the prevalence, aetiology, management, and outcomes of postoperative chylothorax in paediatric patients undergoing cardiac corrective surgery at a tertiary care centre over 15 years. Medical records of paediatric patients who underwent cardiothoracic surgery at the Children’s Heart Center at the American University of Beirut Medical Center between 2007 and 2022 were retrospectively reviewed. Data collection included demographic characteristics, blood parameters, chylous fluid characteristics, diagnostic criteria, treatment modalities, and hospitalisation details. Ethical approval was obtained, and descriptive statistics were employed using SAS 9.4. Among 2,997 children who underwent cardiothoracic surgery, nineteen cases of postoperative chylothorax were identified. The majority were females (63.2%) with a median age of 9 months. Glenn, Fontan, and Blalock–Taussig shunt-related surgeries were the most common operations associated with chylothorax. Single ventricle physiology was the predominant CHD observed (58%). Diagnosis relied primarily on clinical presentation, imaging studies, and triglyceride levels in pleural fluid. Treatment options included conservative dietary modifications, medical therapy such as octreotide, and surgical intervention if necessary. No mortalities were reported, and patients were adequately followed up. This study sheds light on postoperative chylothorax in paediatric cardiac patients, offering insights into its epidemiology, aetiology, clinical features, and treatment outcomes. While conservative and medical approaches effectively managed chylothorax in this group, larger studies are needed to develop standardised diagnostic and treatment protocols, improving outcomes in paediatric patients with postoperative chylothorax.
- 1 March 2025
- Published by Wolters Kluwer Health in JBJS Reviews
- Vol. 13 (3)
Genetics and Epigenetics of Legg-Calvé-Perthes Disease
» Multifactorial Pathogenesis: Legg-Calvé-Perthes disease (LCPD) may result from a complex interplay of genetic, epigenetic, and environmental factors, culminating in avascular necrosis of the femoral head in children aged 4 to 10 years. » Genetic Contributions: Mutations in COL2A1 weaken cartilage integrity, and polymorphisms in IL6 drive inflammatory responses, exacerbating bone resorption and necrosis. » Role of Epigenetics: Epigenetic mechanisms, such as altered DNA methylation and miRNA dysregulation, may modulate disease progression by linking genetic susceptibility to environmental influences. » Environmental Amplifiers: Key environmental risk factors, including maternal smoking, low birth weight, and socioeconomic deprivation, may exacerbate the genetic and epigenetic predisposition to LCPD. » Future Directions: Advancements in genetic screening and epigenetic therapies, such as miRNA modulators and DNA methylation inhibitors, combined with preventive measures like improved prenatal care and reduced smoke exposure, may offer promising avenues for optimizing outcomes in LCPD.
- 1 March 2025
- Published by Wolters Kluwer Health in JBJS Reviews
- Vol. 13 (3)
Genetics and Epigenetics of Legg-Calvé-Perthes Disease
» Multifactorial Pathogenesis: Legg-Calvé-Perthes disease (LCPD) may result from a complex interplay of genetic, epigenetic, and environmental factors, culminating in avascular necrosis of the femoral head in children aged 4 to 10 years. » Genetic Contributions: Mutations in COL2A1 weaken cartilage integrity, and polymorphisms in IL6 drive inflammatory responses, exacerbating bone resorption and necrosis. » Role of Epigenetics: Epigenetic mechanisms, such as altered DNA methylation and miRNA dysregulation, may modulate disease progression by linking genetic susceptibility to environmental influences. » Environmental Amplifiers: Key environmental risk factors, including maternal smoking, low birth weight, and socioeconomic deprivation, may exacerbate the genetic and epigenetic predisposition to LCPD. » Future Directions: Advancements in genetic screening and epigenetic therapies, such as miRNA modulators and DNA methylation inhibitors, combined with preventive measures like improved prenatal care and reduced smoke exposure, may offer promising avenues for optimizing outcomes in LCPD.
- Open Access
- 1 January 2025
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2025 (1)
Thromboembolic Events in the Era of COVID‐19: A Detailed Narrative Review
COVID‐19, caused by the SARS‐CoV‐2 virus, is not only characterized by respiratory symptoms but is also associated with a wide range of systemic complications, including significant hematologic abnormalities. This is a comprehensive review of the current literature, using PubMed and Google Scholar, on the pathophysiology and incidence of thromboembolic events in COVID‐19 patients and thromboprophylaxis. COVID‐19 infection induces a prothrombotic state in patients through the dysregulation of the renin–angiotensin–aldosterone system (RAAS), endothelial dysfunction, elevated von Willebrand factor (vWF), and a dysregulated immune response involving the complement system and neutrophil extracellular traps (NETs). As a result, thromboembolic complications have emerged in COVID‐19 cases, occurring more frequently in severe cases and hospitalized patients. These thrombotic events affect both venous and arterial circulation, with increased incidences of deep venous thrombosis (DVT), pulmonary embolism (PE), systemic arterial thrombosis, and myocardial infarction (MI). While DVT and PE are more common, the literature highlights the potential lethal consequences of arterial thromboembolism (ATE). This review also briefly examines the ongoing discussions regarding the use of anticoagulants for the prevention of thrombotic events in COVID‐19 patients. While theoretically promising, current studies have yielded varied outcomes: Some suggest potential benefits, whereas others report an increased risk of bleeding events among hospitalized patients. Therefore, further large‐scale studies are needed to assess the efficacy and safety of anticoagulants for thromboprophylaxis in COVID‐19 patients.
- 1 January 2025
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2025 (1)
Open AccessThromboembolic Events in the Era of COVID‐19: A Detailed Narrative Review
COVID‐19, caused by the SARS‐CoV‐2 virus, is not only characterized by respiratory symptoms but is also associated with a wide range of systemic complications, including significant hematologic abnormalities. This is a comprehensive review of the current literature, using PubMed and Google Scholar, on the pathophysiology and incidence of thromboembolic events in COVID‐19 patients and thromboprophylaxis. COVID‐19 infection induces a prothrombotic state in patients through the dysregulation of the renin–angiotensin–aldosterone system (RAAS), endothelial dysfunction, elevated von Willebrand factor (vWF), and a dysregulated immune response involving the complement system and neutrophil extracellular traps (NETs). As a result, thromboembolic complications have emerged in COVID‐19 cases, occurring more frequently in severe cases and hospitalized patients. These thrombotic events affect both venous and arterial circulation, with increased incidences of deep venous thrombosis (DVT), pulmonary embolism (PE), systemic arterial thrombosis, and myocardial infarction (MI). While DVT and PE are more common, the literature highlights the potential lethal consequences of arterial thromboembolism (ATE). This review also briefly examines the ongoing discussions regarding the use of anticoagulants for the prevention of thrombotic events in COVID‐19 patients. While theoretically promising, current studies have yielded varied outcomes: Some suggest potential benefits, whereas others report an increased risk of bleeding events among hospitalized patients. Therefore, further large‐scale studies are needed to assess the efficacy and safety of anticoagulants for thromboprophylaxis in COVID‐19 patients.
- Open Access
- 26 March 2024
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 34 (5) , 959-968
NT-proBNP cardiac value in COVID-19: a focus on the paediatric population
NT-proBNP is a peptide related to brain natriuretic peptide, a cardiac biomarker and a member of the natriuretic family of peptides. NT-proBNP has demonstrated its clinical utility in the assessment of a wide spectrum of cardiac manifestations. It is also considered a more precise diagnostic and prognostic cardiac biomarker than brain natriuretic peptide. With the appearance of the Severe Acute Respiratory Syndrome Coronavirus 2 virus and the subsequent COVID-19 pandemic, diagnosis of heart implications began to pose an increasing struggle for the physician. Echocardiography is considered a central means of evaluating cardiac disorders like heart failure, and it is considered a reliable method. However, other diagnostic methods are currently being explored, one of which involves the assessment of NT-proBNP levels. In the literature that involves the adult population, significant positive correlations were drawn between the levels of NT-proBNP and COVID-19 outcomes such as high severity and fatality. In the paediatric population, however, the literature is scarce, and most of the investigations assess NT-proBNP in the context of Multiple Inflammatory Syndrome in Children, where studies have shown that cohorts with this syndrome had elevated levels of NT-proBNP when compared to non-syndromic cohorts. Thus, more large-scale studies on existing COVID-19 data should be carried out in the paediatric population to further understand the prognostic and diagnostic roles of NT-proBNP.
- 26 March 2024
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 34 (5) , 959-968
Open AccessNT-proBNP cardiac value in COVID-19: a focus on the paediatric population
NT-proBNP is a peptide related to brain natriuretic peptide, a cardiac biomarker and a member of the natriuretic family of peptides. NT-proBNP has demonstrated its clinical utility in the assessment of a wide spectrum of cardiac manifestations. It is also considered a more precise diagnostic and prognostic cardiac biomarker than brain natriuretic peptide. With the appearance of the Severe Acute Respiratory Syndrome Coronavirus 2 virus and the subsequent COVID-19 pandemic, diagnosis of heart implications began to pose an increasing struggle for the physician. Echocardiography is considered a central means of evaluating cardiac disorders like heart failure, and it is considered a reliable method. However, other diagnostic methods are currently being explored, one of which involves the assessment of NT-proBNP levels. In the literature that involves the adult population, significant positive correlations were drawn between the levels of NT-proBNP and COVID-19 outcomes such as high severity and fatality. In the paediatric population, however, the literature is scarce, and most of the investigations assess NT-proBNP in the context of Multiple Inflammatory Syndrome in Children, where studies have shown that cohorts with this syndrome had elevated levels of NT-proBNP when compared to non-syndromic cohorts. Thus, more large-scale studies on existing COVID-19 data should be carried out in the paediatric population to further understand the prognostic and diagnostic roles of NT-proBNP.